India is a keymarket for the company’s global plans

Tell us about the growth opportunities opening up in the pharma sector, globally. How is Novo Nordisk poised to leverage them? What are your current and future areas of focus? Why?

The pharma sector continues to present significant growth opportunities globally. Several factors contribute to this positive outlook, including increasing global healthcare expenditure, population aging, rising chronic diseases, technological advancements, and expanding access to healthcare in emerging markets. Research and Development (R&D) advancements in molecular biology, genomics, proteomics, and other fields are driving innovation in drug discovery and development. Targeted therapies, precision medicine, and personalised treatments are gaining prominence, presenting opportunities for pharma companies to develop novel and more effective drugs.

Today, chronic disorders have gained prominence. At Novo Nordisk, we are dedicated to tackling chronic diseases by driving change in diabetes, obesity, rare diseases- haemophilia, growth hormone deficiency, etc., cardiovascular diseases (CVDs), non-alcoholic steatohepatitis (NASH), and more. We are doing this by raising the innovation bar, harnessing the power of scientific excellence, and developing a leading portfolio of superior treatment solutions.

Can you tell us about Novo Nordisk's priority areas of growth in India in the